Posts by: Patricia Inacio PhD

News

Commence Bio has received a patent for STaRT 41 technology, a scientific platform underlying the production of MSC1 cells that work as a novel cancer immunotherapy. STaRT (Stimulated Toll-like Receptor Technology) is inspired ... Read more

June 20, 2016October 12, 2016

Multiple Myeloma Patients Show Lower Risk of Disease Progression with Immunotherapy Combo

News

Results from a Phase 3 clinical trial show a 61% decrease in the risk of disease progression or death in patients with multiple myeloma treated with the immunotherapy daratumumab (Darzalex) ... Read more

March 17, 2016March 17, 2016

First Patient at Wilmot Cancer Institute Takes Part in National Immune Therapy Clinical Trial

News

University of Rochester Medicine’s Wilmot Cancer Institute is participating in a national clinical trial testing a new immune therapy called CAR (chimeric antigen receptor) T-cell therapy to treat cancer. The first ... Read more

February 8, 2016February 8, 2016

Pfizer Partners With Adaptive Biotechnologies in Immuno-Oncology Effort

News

Cancer immunotherapies are a type of treatment that acts by modulating the immune system’s natural responses, either by potentiating its action against cancer cells and/or by inhibiting immunosuppressive mechanisms — ... Read more

January 4, 2016January 4, 2016

Advanced Lung Cancer Patients Seen to Benefit from Pembrolizumab Therapy

News

Yale School of Medicine researchers have discovered that the immune-therapy drug pembrolizumab prolongs overall survival in patients with advanced non-small-cell lung cancer. The study, titled “Pembrolizumab versus docetaxel for previously treated, ... Read more

December 1, 2015December 1, 2015

Tumor-fighting Gene Also Regulates Immune Response to Cancer

News

Researchers at The University of Texas MD Anderson Cancer Center have found a new function for the p53 gene regulating the immune system’s response to lung cancer via its interaction with the PDL1 ... Read more

November 20, 2015November 20, 2015

Memgen’s IO Drug Shows Potential in Early Study of B16 Melanomas

News

Memgen biopharmaceutical recently presented a poster, entitled “Induction of Potent Systemic Anti-Melanoma Immunity through Intratumoral CD40 Activation and Checkpoint Blockade,” describing the positive results of Memgen’s lead product, ISF35, in preclinical studies with ... Read more

November 17, 2015November 17, 2015

ImmunoCellular Therapeutics and MD Anderson Target a Possible Cancer Killer

News

ImmunoCellular Therapeutics, a clinical-stage company developing immune-based therapies for several cancers, recently announced it has established a research partnership with Dr. Cassian Yee, of the University of Texas MD Anderson Cancer Center, ... Read more

November 16, 2015November 16, 2015

OncoMed Cancer Therapeutic Shows Promise in Preclinical Study

News

OncoMed Pharmaceuticals, Inc., reported that anti-DLL4, a cancer therapeutic with multiple mechanisms of action, demonstrated improved anti-tumor and immune responses in different mouse models of tumors when combined with anti-VEGF and anti-PD1. The ... Read more

November 13, 2015November 13, 2015

ATLAS Shows Promise in Distinguishing Cancer Patients Who Respond to Immunotherapy

News

Genocea Biosciences, Inc. recently announced positive results from a pilot study on ATLAS, the company’s lead technology, when applied to cancer patients treated with immunotherapies. The results were announced in ... Read more